Erythrodermic Psoriasis Managed with Risankizumab

Abdulmajeed Alajlan; Abdulaziz Madani; Tala Ammar Qadoumi; Alhanouf Aljaloud; Mohammed Alessa

doi:10.1159/000525774

Erythrodermic Psoriasis Managed with Risankizumab

Case Rep Dermatol. 2022 Aug 19;14(2):219-224. doi: 10.1159/000525774. eCollection 2022 May-Aug.

Authors

Abdulmajeed Alajlan¹, Abdulaziz Madani², Tala Ammar Qadoumi¹, Alhanouf Aljaloud³, Mohammed Alessa³

Affiliations

¹ Dermatology Department, King Saud University and King Saud University Medical City, Riyadh, Saudi Arabia.
² Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
³ College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Abstract

Erythrodermic psoriasis (EP) is a severe, often refractory, variant of psoriasis. Due to the high morbidity and mortality rate associated with EP and other causes of erythroderma, they are often classified as dermatologic emergencies. EP is usually a therapeutic challenge, where topical and conventional systemic therapies have yielded a less than satisfactory result in several patients. Furthermore, there are a limited number of studies evaluating other therapeutic modalities, such as biologic agents, with no clear treatment guidelines. In this case report, we present a patient who was diagnosed as a case of EP and showed an impressive response to risankizumab.

Keywords: Biological therapy; Erythroderma; Erythrodermic psoriasis; Psoriasis; Psoriasis treatment; Risankizumab.

Publication types

Case Reports